Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

Trading Update

25 Jan 2006 07:01

Plant Health Care PLC25 January 2006 Embargoed until 07.00 25 January 2006 Plant Health Care plc POST YEAR-END TRADING AND PRODUCT UPDATE Major support for Pre-Tect Product Increasing Interest for Myconate Trading Plant Health Care plc ("PHC" or the "Company"), a leading provider of naturalplant fertility products, is pleased to announce that since the update providedin its interim statement on 19 September 2005, it has continued to make goodprogress. Although some supplier delays have resulted in sales for the yearended 31 December 2005 being slightly below earlier expectations, better grossmargins and cost containment have been achieved which it believes will enablethe Company to report in line with expectations, before exceptional items, aspreviously referred to. The current year has started well, with the John Deere contract now wellunderway and indications that a number of new agreements will providesignificant revenue growth in Europe. The Company has, however, already begun toinvest in additional people, mainly in sales, to manage this growth and to moveforward some other initiatives, including Pre-Tect and Myconate testing. Major support for Pre-Tect Product The Company is pleased to announce very encouraging results followingindependent trials of its newly formulated, naturally derived Pre-Tect product.The tests were carried out in the UK on lettuce and spinach crops by several ofthe UK's largest salad growing companies and took place in several areas withdiverse climate and soil conditions. The tests were full farm replicated trialson whole head and cut leaf salads. Pre-Tect consistently increased the shelflife of the crops by 25% to 40% (3-5 days). Based on these trials, PHC hasentered into supply agreements with several of the largest European saladgrowers. Additionally, one of the largest supermarket chains in the UK isspecifying the use of Pre-Tect on all its salad crop purchases. Increasing Interest for Myconate PHC reported on the early results of its Myconate testing on 15 December 2005and still has tests ongoing with some of the world's largest agro chemical andseed companies. Mainly as a result of the trials that have already beencompleted in France, the largest corn growing country in Europe, a number ofmajor seed companies have expressed interest in expanding trials in 2006 andhave made initial enquiries about entering into distribution agreements. The Board is of the view that it should not consider any such arrangements untilafter completion of all the existing trials. At that time the Company will be ina better position to determine the most commercially advantageous routes tomarket for this product. PHC is currently reviewing various options for the development andcommercialisation of Myconate, which, it believes, will have applications acrossa wide range of the world's most valuable crops and agricultural plants, inparticular maize and soybean, the two highest value row crops in the world. PHC expects to release its full year results early March 2006 and it will thenprovide a further update on the status of the ongoing Myconate trials. For further information please contact: John Brady Jeremy Carey / Christian Taylor-WilkinsonPlant Health Care Tavistock CommunicationsTel: 020 7920 3150 (on 25/26 January) Tel: 020 7920 3150Tel: 001 6035253702 (thereafter) This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments
12th Jan 20237:00 amRNSNovozymes Distribution Agreement
9th Jan 20237:00 amRNSInvestor Presentation
22nd Dec 20227:00 amRNSNew Products Submitted for Regulatory Approval
28th Oct 20227:00 amRNSRegistration of Harpin in France
28th Oct 20227:00 amRNSNew distribution agreement with EDAF
27th Oct 20227:00 amRNSTrading Update
14th Oct 20225:11 pmRNSDirector/PDMR Shareholding
14th Oct 202210:39 amRNSDirector / PDMR Shareholding
26th Sep 20227:00 amRNSInterim Results
22nd Aug 20227:00 amRNSTrials agreement signed with Agrii UK
12th Aug 20227:00 amRNSGrant of Options
10th Aug 20225:04 pmRNSDirector/PDMR Shareholding
21st Jul 20222:41 pmRNSHolding(s) in Company
18th Jul 20227:02 amRNSInvestor Presentation
18th Jul 20227:00 amRNSPost-Close Trading Update
22nd Jun 202212:37 pmRNSResult of AGM
21st Jun 20227:00 amRNSCompletion of Nominated Adviser due diligence
20th Jun 20227:00 amRNSLong-term Harpin Production and Supply Agreement
6th Jun 20228:00 amRNSHolding(s) in Company
6th Jun 20228:00 amRNSHolding(s) in Company
1st Jun 20222:31 pmRNSDirector/PDMR Shareholding
25th May 20225:23 pmRNSHolding(s) in Company
23rd May 20227:30 amRNSAnnual Report & Accounts and Notice of AGM
23rd May 20227:00 amRNSNew distribution agreement with Nutrien
16th May 20227:00 amRNSHolding(s) in Company
12th May 20227:15 amRNSCEO appointment and Board changes
12th May 20227:00 amRNSResults for the year ended 31 December 2021
28th Apr 20227:00 amRNSChange of Adviser
21st Apr 20222:27 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.